Publications
Detailed Information
Early Compliance and Efficacy of Sublingual Immunotherapy in Patients with Allergic Rhinitis for House Dust Mites
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Hyun | - |
dc.contributor.author | Han, Doo Hee | - |
dc.contributor.author | Mo, Ji-hun | - |
dc.contributor.author | Kim, Jeong-Whun | - |
dc.contributor.author | Lee, Chul Hee | - |
dc.contributor.author | Rhee, Chae-Seo | - |
dc.contributor.author | Min, Yang-Gi | - |
dc.contributor.author | Kim, Dong-Young | - |
dc.date.accessioned | 2012-07-05T00:44:27Z | - |
dc.date.available | 2012-07-05T00:44:27Z | - |
dc.date.issued | 2009-09 | - |
dc.identifier.citation | CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY; Vol.2 3; 136-140 | ko_KR |
dc.identifier.issn | 1976-8710 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78524 | - |
dc.description.abstract | Objectives. Sublingual immunotherapy (SLIT) has recently received much attention around the world as a treatment for allergic rhinitis. This study aimed to investigate the efficacy and adverse effects of SLIT in Korean patients with allergic rhinitis caused by house dust mites. The treatment compliance and the patient satisfaction with SLIT were also assessed. Methods. The patients who were sensitized to Dermatophagoides pteronyssinus and Dermatophagoides farinae and who started SLIT between November 2007 and July 2008 were included in this study. The symptom questionnaires, which included items on rhinorrhea, sneezing, nasal obstruction, itchy nose, olfactory disturbance, eye discomfort and sleep disturbance, were obtained before and 6 months after SLIT. The patient satisfaction and the adverse effects were also investigated. Results. One hundred forty-two patients started SLIT and 98 of them continued SLIT for 6 months or more. Ninety-two of the 98 patients completed the questionnaires. The duration of receiving SLIT was 9.8 months on average (range, 6 to 13 months). All the symptoms of allergic rhinitis were improved with SLIT. Forty-five percent of the patients were satisfied for SLIT, while 12% were unsatisfied. The incidence of adverse effects was 12% during maintenance therapy, although it was 48% during the up-dosing phase. The drop-out rate of SLIT was 31.0%. Conclusion. The subjective symptoms were improved with SLIT in Korean patients with allergic rhinitis for house dust mites. Yet the drop out rate was high despite of the symptomatic improvement. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN SOC OTORHINOLARYNGOL | ko_KR |
dc.subject | Allergic rhinitis | ko_KR |
dc.subject | Immunotherapy | ko_KR |
dc.subject | Compliance | ko_KR |
dc.title | Early Compliance and Efficacy of Sublingual Immunotherapy in Patients with Allergic Rhinitis for House Dust Mites | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 장현 | - |
dc.contributor.AlternativeAuthor | 한두희 | - |
dc.contributor.AlternativeAuthor | 모지헌 | - |
dc.contributor.AlternativeAuthor | 김정훈 | - |
dc.contributor.AlternativeAuthor | 김동영 | - |
dc.contributor.AlternativeAuthor | 이철희 | - |
dc.contributor.AlternativeAuthor | 민양기 | - |
dc.contributor.AlternativeAuthor | 이재서 | - |
dc.identifier.doi | 10.3342/ceo.2009.2.3.136 | - |
dc.citation.journaltitle | CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY | - |
dc.description.citedreference | Roder E, 2008, CLIN EXP ALLERGY, V38, P1659, DOI 10.1111/j.1365-2222.2008.03060.x | - |
dc.description.citedreference | Esch RE, 2008, CURR OPIN OTOLARYNGO, V16, P260 | - |
dc.description.citedreference | Frew AJ, 2008, NEW ENGL J MED, V358, P2259 | - |
dc.description.citedreference | BOUSQUET J, 2008, ALLERGY S, V86, P8 | - |
dc.description.citedreference | Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x | - |
dc.description.citedreference | Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x | - |
dc.description.citedreference | Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x | - |
dc.description.citedreference | Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003 | - |
dc.description.citedreference | Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358 | - |
dc.description.citedreference | Passlacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P946, DOI 10.1016/j.jaci.2005.12.1312 | - |
dc.description.citedreference | Canonica GW, 2006, ALLERGY, V61, P20 | - |
dc.description.citedreference | PASSALACQUA G, 2006, INFLAMM ALLERGY DRUG, V5, P43 | - |
dc.description.citedreference | RIENZO VD, 2005, CLIN EXP ALLERGY, V35, P560 | - |
dc.description.citedreference | KIM DY, 2004, KOREAN J OTOLARYNGOL, V47, P132 | - |
dc.description.citedreference | WILSON DR, 2003, COCHRANE DB SYST REV, P2893 | - |
dc.description.citedreference | NUHOGLU Y, 2003, J INVESTIG ALLERGOL, V17, P375 | - |
dc.description.citedreference | Lombardi C, 2001, ALLERGY, V56, P989 | - |
dc.description.citedreference | Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x | - |
dc.description.citedreference | Purello-D`Ambrosio F, 1999, ALLERGY, V54, P968 | - |
dc.description.citedreference | Pradalier A, 1999, ALLERGY, V54, P819 | - |
dc.description.citedreference | Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356 | - |
dc.description.citedreference | CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305 | - |
dc.description.tc | 6 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.